Results 91 to 100 of about 1,941 (170)

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3902-3913, November 2026.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub   +3 more
wiley   +1 more source

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

open access: yesCells
Kinases are highly explored drug targets due to their central role in cell growth, differentiation, and cell death, as well as their relationship to cancer initiation and progression.
Eduardo Bravo   +4 more
doaj   +1 more source

Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie   +4 more
wiley   +1 more source

Scalable Arrayed T‐cell CRISPR Screening in Autologous Tumor Co‐cultures to Prioritize Combination Partners for T‐cell Engagers

open access: yesCurrent Protocols, Volume 6, Issue 11, November 2026.
Abstract T‐cell‐engaging therapies (TCE) have shown clinical promise in hematologic malignancies, but the T‐cell‐intrinsic determinants of TCE‐mediated cytotoxicity remain incompletely defined. This is in part because functional studies in patient‐derived primary samples have been technically challenging.
Keenan Ernste   +9 more
wiley   +1 more source

Salicylic Acid as a Food‐Derived Bioactive Constituent of Tiaoqi Daozhi Decoction: A Potential Functional Food Ingredient to Restoring Gut Barrier Function in Constipation‐Predominant IBS

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
Tiaoqi Daozhi Decoction (TQDZD) is a classic formulation composed of eight medicine‐food homologous botanicals. UPLC‐MS/MS profiling identified 1962 non‐redundant compounds in its aqueous extract, predominantly phenolic acids and flavonoids, of which 107 metabolites were systemically bioavailable.
Min Duan   +4 more
wiley   +1 more source

Integrated Multi‐Omics Analysis of Polygonatum odoratum Polysaccharide in D‐Galactose‐Treated Mice Reveals Changes in Oxidative Stress Markers and Gut Microbiota

open access: yesFood Science &Nutrition, Volume 14, Issue 11, November 2026.
This study evaluated the effects of Polygonatum odoratum polysaccharide (POP) in D‐galactose‐treated mice using hippocampal histology, oxidative stress measurements, and integrated multi‐omics analyses. Results showed improved hippocampal histology and oxidative stress markers, accompanied by changes in gut bacterial composition, serum metabolites, and
Wenjian Li   +4 more
wiley   +1 more source

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale   +106 more
wiley   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He   +4 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy